The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer Patients

NCT06245759 | Unknown

• 1 other identifier: TJIRB20230888
• Study Type: observational
• Target: 120,000
• Locations: 1 country
• Sites: 1

Brief Summary

Based on large sample size studies at home and abroad, the prognosis of patients with non-muscular invasive bladder cancer in different sites undergoing transurethral bladder tumor resection was determined, providing important guidance for subsequent clinical treatment and surgical instrument development.

Conditions

Non-Muscle-Invasive Bladder Cancer; Bladder Cancer

Outcome Measures

Primary Outcomes (2)

• Overall survival time

  OS, defined as the time from the first diagnosis to death from any cause or the last follow-up for surviving patients

  up to 20 years

• Recurrence free survival time

  Recurrence-free survival (RFS) is the time from the time a patient achieved complete response after antineoplastic therapy to the time of recurrence or the end of follow-up. The longer the relapse-free survival time, the better the efficacy of anti-tumor therapy.

  up to 16 years

Study Arms (2)

the U.S. National Cancer Center SEER database

The Chinese NMIBC cohort includes patients from January 1996 to December 2019 at 15 institutions.

Other: This was a retrospective study and no patient intervention was performed

the Chinese Bladder Cancer Alliance CBCC database

SEER\*Stat software (version 8.4.1.1) collected 17 registries cohort data on NMIBC patients diagnosed between 2000 and 2020.

Other: This was a retrospective study and no patient intervention was performed

Interventions

This was a retrospective study and no patient intervention was performed OTHER

This was a retrospective study and no patient intervention was performed

the Chinese Bladder Cancer Alliance CBCC database; the U.S. National Cancer Center SEER database

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study utilized the Chinese NMIBC cohort as well as the SEER 17 registries cohort for its investigation. The Chinese NMIBC cohort contains data of patients between January 1996 and December 2019, at 14 institutions. SEER\*Stat software (version 8.4.1.1) was used for collecting 17 registries cohort data on patients diagnosed with NMIBC between 2000 and 2020.

You may qualify if:

• Initially diagnosed with non-muscular invasive bladder cancer (NMIBC) who underwent TURBT or partial cystectomy.
• The follow-up data of the patients were complete.
• The tumor location information were complete.

You may not qualify if:

• Patients with unknown survival time or missing tumor location information were excluded.
• Exclude patients with missing pathological results.
• Exclude patients who have had TURBT before.

Sponsors & Collaborators

• Huazhong University of Science and Technology: lead

Study Sites (1)

Ke Chen

Wuhan, Hubei, 430022, China

RECRUITING

Related Publications (1)

• Liu L, Li K, Wang SG, Wang J, Yao Z, Xie Y, Ji Z, Chen Z, Hu H, Chen H, Hu J, Hou Y, Liu Z, Li Y, Ding Y, Kuang Y, Xun Y, Hu J, Zhang J, Li H, Chong T, Bi J, Wang Z, Wang Y, Zhang P, Wei Q, Chen Z, Li L, Huang J, Liu Z, Chen K; Chinese Bladder Cancer Consortium. The prognostic impact of tumor location in nonmuscle-invasive bladder cancer patients undergoing transurethral resection: insights from a cohort study utilizing Chinese multicenter and SEER registries. Int J Surg. 2024 Sep 1;110(9):5641-5651. doi: 10.1097/JS9.0000000000001675.

  PMID: 38788195 DERIVED

MeSH Terms

Conditions

Non-Muscle Invasive Bladder Neoplasms; Urinary Bladder Neoplasms

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases

Study Officials

• Ke Chen, MD/PhD

  Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

  STUDY CHAIR

Central Study Contacts

Pu Zhou, MD

CONTACT

+86 27 83662379; tongjihlunli@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director

Study Record Dates

• First Submitted: January 23, 2024
• First Posted: February 7, 2024
• Study Start: August 31, 2023
• Primary Completion: December 31, 2024
• Study Completion: December 31, 2024
• Last Updated: February 7, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)